XNASPEPG
Market cap96mUSD
Jan 10, Last price
2.97USD
1D
-13.91%
1Q
-66.29%
IPO
-75.04%
Name
PepGen Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-79m
L+13.78%
CFO
-69m
L+16.42%
Profile
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 85,950 | 68,794 | |||
Unusual Expense (Income) | |||||
NOPBT | (85,950) | (68,794) | |||
NOPBT Margin | |||||
Operating Taxes | 73 | 3,706 | |||
Tax Rate | |||||
NOPAT | (86,023) | (72,500) | |||
Net income | (78,626) 13.78% | (69,104) 153.30% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (189) | 112,193 | |||
BB yield | 0.12% | -35.39% | |||
| Debt | |||||
Debt current | 6,008 | 5,553 | |||
Long-term debt | 37,204 | 43,515 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (67,195) | (134,157) | |||
| Cash flow | |||||
Cash from operating activities | (68,997) | (59,265) | |||
CAPEX | (2,599) | (3,755) | |||
Cash from investing activities | (32,003) | (3,755) | |||
Cash from financing activities | (189) | 112 | |||
FCF | (84,523) | (101,748) | |||
| Balance | |||||
Cash | 110,407 | 181,752 | |||
Long term investments | 1,473 | ||||
Excess cash | 110,407 | 183,225 | |||
Stockholders' equity | (181,446) | 114,505 | |||
Invested Capital | 312,975 | 86,412 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 23,796 | 23,713 | |||
Price | 6.80 -49.14% | 13.37 | |||
Market cap | 161,813 -48.96% | 317,045 | |||
EV | 94,618 | 400,328 | |||
EBITDA | (84,766) | (68,301) | |||
EV/EBITDA | |||||
Interest | 3,396 | ||||
Interest/NOPBT | |||||